-
Notifications
You must be signed in to change notification settings - Fork 2
0 BSIC inittowinit
**Value Proposition(s) ** TK to be moved to Main Readme @ launch
-
Potential to obtain a CPIM with the FDA
-
Alternative or combination option of COA tool pathway.COA info .
-
Position Blockchain-based Technology in a position to make a substantial positive impact at the December 18, 2017, meeting "Patient focused drug development" Meeting Information
-
Success of one or more of the 3 above items is a major step towards opening the funding flood gates for project above and beyond the scope of TrialPhi. Page 13 here for example
And a few more channels:
- Small Innovation Research Program
- Small Business Technology Program
- Grants & Funding Opportunities at NIH
From page 2 of 6 FDA CPIM INFO DOC. Potential outcomes of CPIMs include efforts leading to:
- Regulatory submissions of clinical trials with new designs and methods
- Proposals for the use of emerging technologies
- Proposals for biomarker qualification or the use of biomarkers in regulatory submissions
- Natural history studies
- Public workshops and future collaboration of FDA with external parties
- Development of new guidance
- Formation of new consortia and public-private partnerships to advance regulatory science efforts
MVP Functions: Tracking of De-identified Patient Data for 2 Key Metrics. 1 is a MAJOR pain point to all parties involved and the other is patient reported outcomes via Quality of Life Survey.
Concomitant Medications (Con-Meds) - Medications taken by the patient before during and after study going back sometimes 5 to 10 years.
- Data fields for interface: ID, Name, Description, Dosage, Frequency, Start Date, Stop Date, Notes.
- QOL Survey - ID, Date, Time, Note, Field 1, Field 2, ...., Field 5. -as simple as it seems .
Lots of refinement still to happen in the next 18 hours but wanted to get this pushed out there for digestion and any and all feedback.
Tear it apart